Sanara MedTech is like a specialized, emerging Smith & Nephew focused exclusively on advanced wound and skin care products.

Think of Sanara MedTech as a standalone company doing what a dedicated division of 3M Healthcare might do, but solely concentrated on innovative wound and skin healing technologies.

• CellerateRX Surgical Activated Collagen powder and gel: These products are used in various surgical specialties to help promote patient healing.
• Biako¯s Antimicrobial Skin and Wound Cleanser: A patented product designed to disrupt extracellular polymeric substances and eradicate mature biofilm microbes.
• Biako¯s Antimicrobial Wound Gel: An antimicrobial hydrogel wound dressing effective against planktonic microbes, as well as immature and mature biofilms.
• Biako¯s Antimicrobial Skin and Wound Irrigation Solution: A solution used for irrigating skin and wounds, likely with antimicrobial properties similar to other Biakōs products.
• HYCOL Hydrolyzed Collagen Powder and Gel: A medical hydrolysate of Type I bovine collagen used for managing various full and partial thickness wounds, including ulcers.
• FORTIFY TRG: A freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet used for advanced wound care.
• FORTIFY FLOWABLE extracellular matrix: An advanced wound care device provided in a flowable form.
• VIM Amnion Matrix: A single layer sheet of amnion tissue used in wound management.

Sanara MedTech (SMTI) primarily sells its wound and skin care products to other companies and organizations within the healthcare sector, rather than directly to individuals. Based on the company description, its major customers are:

• Physicians
• Hospitals
• Clinics
• Post-acute care settings

The company description does not provide the names of specific customer companies (e.g., individual hospital systems or large clinic chains) nor their public symbols.

Seth Yon, President and Chief Executive Officer

Seth Yon was appointed President and Chief Executive Officer of Sanara MedTech in September 2025. He joined the company in 2018 and has held various senior-level management positions, including President and Chief Commercial Officer. Prior to joining Sanara, Mr. Yon served as Vice President of Iroquois Industrial Group, where he guided multiple divisions in product offerings to the medical, educational, and automotive industries.

Elizabeth Taylor, Chief Financial Officer

Elizabeth Taylor was appointed Chief Financial Officer of Sanara MedTech, effective January 15, 2025. She brings over 25 years of financial experience, including previous roles as CFO of a medical device company (Imbed Biosciences) and COO of multiple hedge funds. Ms. Taylor also served as a member of the investment team at the private equity firm Thomas H. Lee Partners, L.P. She founded and managed Burnett Taylor Consulting, LLC, serving as an umbrella financial advisor.

Ron Nixon, Executive Chairman

Ron Nixon is the Executive Chairman of Sanara MedTech, a position he has held since May 2019. He previously served as the company's Chief Executive Officer until September 2025. Mr. Nixon is also the Founder and Managing Partner of The Catalyst Group, Inc., and serves on the board of directors for several other privately held companies.

Jake Waldrop, Chief Operating Officer

Jake Waldrop joined Sanara MedTech as Chief Operating Officer in April 2024. He has 20 years of experience in leading cross-functional teams in the technology and medical device industries. Before joining Sanara, he was the Chief Financial Officer for Trilliant Surgical, and following its sale to Enovis, he became the Vice President of Finance and Integrations for Enovis' Foot and Ankle division.

Nina Bionda, Chief R&D Officer

Nina Bionda was appointed Chief R&D Officer for Sanara MedTech in May 2025, leading the Research & Development team. She joined the company in September 2022 as the Vice President of Research & Development. Prior to Sanara, Ms. Bionda spent seven years at a preclinical Contract Research Organization (CRO) specializing in the comprehensive evaluation of medical devices.

1. Weak Financial Position and High Debt Load
   Sanara MedTech's financial health presents a significant risk, characterized by a weak balance sheet and a substantial long-term debt. As of Q3 2025, the company reported $45 million in long-term debt against $15 million in cash, with an associated high interest rate exceeding 13%. A notable concern is the "payment in kind" (PIK) interest, which causes the loan balance to increase over time, creating a compounding debt situation. The company has also experienced widening net losses, with a net loss of $9.9 million in 2024 and $5.5 million in the first half of 2025, despite revenue growth. This financial strain is exacerbated by past strategic missteps, such as the discontinuation of the Tissue Health Plus (THP) segment, which involved over $30 million in investments and resulted in significant cash burn and a loss of investor trust. The need to deleverage and refinance this high-interest debt is critical for the company's long-term stability and growth.
2. Product Development, Regulatory Approval, and Commercialization Risks
   As a medical technology company, Sanara MedTech is highly exposed to risks associated with the development, regulatory approval, and successful commercialization of its new and existing products. There are inherent uncertainties in obtaining necessary regulatory clearances, such as the FDA's 510(k) clearance, for new medical devices and technologies like OsStic. The efficacy and adoption rates of these products in the market also represent significant risks, as successful commercialization depends heavily on market and customer acceptance, and the extent of product demand. Furthermore, the company faces risks related to "off-label" product promotion, which could lead to substantial monetary penalties, business license suspensions, product recalls, and other enforcement actions.
3. Intense Competition and Market Acceptance Challenges
   Sanara MedTech operates in the highly competitive healthcare sector, specifically within the wound and skin care, and surgical products markets. The company faces competition from numerous established players and emerging technologies, which can lead to pricing pressures and challenges in gaining market share. Rapid technological advancements in the medical field pose a risk of making existing products obsolete. The company's growth relies on an expanding independent distribution network and dedicated clinical support, meaning any disruption to this network or a lack of adoption by healthcare providers could significantly impact its market penetration and revenue. Successfully fending off competitors and ensuring sustained market acceptance for its specialized products remain ongoing challenges for Sanara MedTech.

Sanara MedTech Inc. (SMTI) operates in various segments of the wound and skin care market. The addressable markets for its main products and services, primarily within wound care, are substantial and are projected to grow.

Collagen Products (CellerateRX Surgical Activated Collagen, HYCOL Hydrolyzed Collagen Powder and Gel)

The global collagen dressing market was valued at approximately $1.29 billion in 2024 and is projected to reach $1.93 billion by 2030. More specifically, the global collagen-based wound dressings market was valued at $423 million in 2024 and is projected to grow to $676 million by 2032. North America is a significant region in this market, holding approximately 38% of the global collagen-based wound dressings market revenue in 2024. The broader North American medical collagen market was valued at $1,186.21 million in 2024 and is projected to reach $1,764.63 million by 2032.

Antimicrobial Products (Biako¯s Antimicrobial Skin and Wound Cleanser, Biako¯s Antimicrobial Wound Gel)

The global antimicrobial wound care dressings market is projected to grow from $3.1 billion in 2025 to $5 billion by 2035. Similarly, the global antimicrobial wound cleanser market was estimated at $560.21 million in 2025 and is predicted to reach approximately $869.99 million by 2035. North America is a dominant region in the antimicrobial wound care dressing market, accounting for approximately 45% of the global share. The North America wound cleanser products market held a share of 37.47% in 2024.

Extracellular Matrix (ECM) Products (FORTIFY TRG, FORTIFY FLOWABLE extracellular matrix)

The global extracellular matrix market is estimated to be valued at $44.2 million in 2025 and is expected to reach $74.8 million by 2032. North America is expected to be the largest market for extracellular matrix products, accounting for over 40.5% of the market share in 2025.

Amniotic Matrix Products (VIM Amnion Matrix)

The global amniotic membrane market size is estimated at $3.75 billion in 2026 and is forecast to reach $6.58 billion by 2031. Another estimate places the global amniotic membrane market at $3.60 billion in 2023, projected to reach $8.50 billion by 2030. North America contributed 41.85% of the revenue in the amniotic membrane market in 2025.

Expected Drivers of Future Revenue Growth for Sanara MedTech (SMTI)

Sanara MedTech Inc. (SMTI) is expected to drive future revenue growth over the next 2-3 years through several strategic initiatives focused on its core surgical wound and skin care business:

1. Increased Market Penetration and Geographic Expansion: The company aims to expand sales of its soft tissue repair products, including CellerateRX, by increasing market penetration within existing accounts and extending its reach into new geographic areas across the U.S. This strategy involves maximizing the use of its products in current facilities and expanding into additional surgical specialties beyond its traditional focus areas like ortho and spine, such as trauma, vascular, and general surgery.
2. Expansion of the Independent Distribution Network: Sanara MedTech is actively growing its independent distribution network in both new and existing U.S. markets. This expansion is crucial for increasing access to healthcare providers and ultimately driving higher product sales.
3. Introduction and Growth of New Products and Penetration of New Surgical Specialties: A significant driver of revenue growth will come from the introduction of new products and continued focus on recently launched ones. The company plans to introduce its OsStic Synthetic Injectable Structural Bio-Adhesive to the U.S. market. Additionally, the BIASURGE Advanced Surgical Solution, having secured an Innovative Technology contract from Vizient, Inc., is anticipated to gain broader access to Vizient's healthcare facility customers.
4. Focused Strategy on the Core Surgical Business: Sanara MedTech has strategically decided to discontinue its Tissue Health Plus (THP) operations to concentrate resources on its highly profitable and growing Sanara Surgical segment. This streamlined focus on the surgical business, which includes soft tissue repair and bone fusion products, is expected to enhance overall revenue growth and profitability by leveraging its strong performance in this segment.

Share Issuance

• In February 2021, Sanara MedTech Inc. completed an underwritten public offering of 1,265,000 shares of common stock at $25.00 per share, generating gross proceeds of $31.6 million.
• The net proceeds from this offering were intended to expand the salesforce, further develop products, services, and technologies, support clinical studies, and for general corporate purposes, including working capital.

Inbound Investments

• Sanara MedTech Inc. received $31.6 million in gross proceeds from a public offering of common stock in February 2021.

Outbound Investments

• The company reported cash acquisitions of -$2.5 million in fiscal year 2023 and -$9.9 million in fiscal year 2022.
• Investment activities were reported as -$12.66 million in the last 12 months, which provided weak support for R&D spending.

Capital Expenditures

• Capital expenditures in the last 12 months amounted to -$4.62 million.
• Sanara MedTech's cash flow statements indicate capital expenditures of -$0.5 million for fiscal year 2024, -$0.2 million for fiscal year 2023, and -$0.1 million for fiscal year 2022.
• The company expects no material cash spend on its Tissue Health Plus (THP) segment after 2025, following the decision to discontinue THP operations and reallocate resources to its core surgical business.